Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

The current standard of care for patients with locally advanced or metastatic non–small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)–sensitizing mutations is treatment with a first-generation or second-generation EGFR-TKI such as…

http://ift.tt/2hzUGTf